Rationalising the role of Keratin 9 as a biomarker for Alzheimer’s disease
Keratin 9 was recently identified as an important component of a biomarker panel which demonstrated a high diagnostic accuracy (87%) for Alzheimer’s disease (AD). Understanding how a protein which is predominantly expressed in palmoplantar epidermis is implicated in AD may shed new light on the mech...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Published: |
Nature Publishing Group
2016
|
| Subjects: | |
| Online Access: | https://eprints.nottingham.ac.uk/32385/ |
| _version_ | 1848794397092610048 |
|---|---|
| author | Richens, Joanna L. Spencer, Hannah L. Butler, Molly Cantlay, Fiona Vere, Kelly-Ann Bajaj, Nin Morgan, Kevin O'Shea, Paul |
| author_facet | Richens, Joanna L. Spencer, Hannah L. Butler, Molly Cantlay, Fiona Vere, Kelly-Ann Bajaj, Nin Morgan, Kevin O'Shea, Paul |
| author_sort | Richens, Joanna L. |
| building | Nottingham Research Data Repository |
| collection | Online Access |
| description | Keratin 9 was recently identified as an important component of a biomarker panel which demonstrated a high diagnostic accuracy (87%) for Alzheimer’s disease (AD). Understanding how a protein which is predominantly expressed in palmoplantar epidermis is implicated in AD may shed new light on the mechanisms underlying the disease. Here we use immunoassays to examine blood plasma expression patterns of Keratin 9 and its relationship to other AD-associated proteins. We correlate this with the use of an in silico analysis tool VisANT to elucidate possible pathways through which the involvement of Keratin 9 may take place. We identify possible links with Dickkopf-1, a negative regulator of the wnt pathway, and propose that the abnormal expression of Keratin 9 in AD blood and cerebrospinal fluid may be a result of blood brain barrier dysregulation and disruption of the ubiquitin proteasome system. Our findings suggest that dysregulated Keratin 9 expression is a consequence of AD pathology but, as it interacts with a broad range of proteins, it may have other, as yet uncharacterized, downstream effects which could contribute to AD onset and progression. |
| first_indexed | 2025-11-14T19:15:32Z |
| format | Article |
| id | nottingham-32385 |
| institution | University of Nottingham Malaysia Campus |
| institution_category | Local University |
| last_indexed | 2025-11-14T19:15:32Z |
| publishDate | 2016 |
| publisher | Nature Publishing Group |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | nottingham-323852020-05-04T17:42:01Z https://eprints.nottingham.ac.uk/32385/ Rationalising the role of Keratin 9 as a biomarker for Alzheimer’s disease Richens, Joanna L. Spencer, Hannah L. Butler, Molly Cantlay, Fiona Vere, Kelly-Ann Bajaj, Nin Morgan, Kevin O'Shea, Paul Keratin 9 was recently identified as an important component of a biomarker panel which demonstrated a high diagnostic accuracy (87%) for Alzheimer’s disease (AD). Understanding how a protein which is predominantly expressed in palmoplantar epidermis is implicated in AD may shed new light on the mechanisms underlying the disease. Here we use immunoassays to examine blood plasma expression patterns of Keratin 9 and its relationship to other AD-associated proteins. We correlate this with the use of an in silico analysis tool VisANT to elucidate possible pathways through which the involvement of Keratin 9 may take place. We identify possible links with Dickkopf-1, a negative regulator of the wnt pathway, and propose that the abnormal expression of Keratin 9 in AD blood and cerebrospinal fluid may be a result of blood brain barrier dysregulation and disruption of the ubiquitin proteasome system. Our findings suggest that dysregulated Keratin 9 expression is a consequence of AD pathology but, as it interacts with a broad range of proteins, it may have other, as yet uncharacterized, downstream effects which could contribute to AD onset and progression. Nature Publishing Group 2016-03-14 Article PeerReviewed Richens, Joanna L., Spencer, Hannah L., Butler, Molly, Cantlay, Fiona, Vere, Kelly-Ann, Bajaj, Nin, Morgan, Kevin and O'Shea, Paul (2016) Rationalising the role of Keratin 9 as a biomarker for Alzheimer’s disease. Scientific Reports, 6 (22962). pp. 1-12. ISSN 2045-2322 keratin 9 Alzheimer's disease http://www.nature.com/articles/srep22962 doi:10.1038/srep22962 doi:10.1038/srep22962 |
| spellingShingle | keratin 9 Alzheimer's disease Richens, Joanna L. Spencer, Hannah L. Butler, Molly Cantlay, Fiona Vere, Kelly-Ann Bajaj, Nin Morgan, Kevin O'Shea, Paul Rationalising the role of Keratin 9 as a biomarker for Alzheimer’s disease |
| title | Rationalising the role of Keratin 9 as a biomarker for Alzheimer’s disease |
| title_full | Rationalising the role of Keratin 9 as a biomarker for Alzheimer’s disease |
| title_fullStr | Rationalising the role of Keratin 9 as a biomarker for Alzheimer’s disease |
| title_full_unstemmed | Rationalising the role of Keratin 9 as a biomarker for Alzheimer’s disease |
| title_short | Rationalising the role of Keratin 9 as a biomarker for Alzheimer’s disease |
| title_sort | rationalising the role of keratin 9 as a biomarker for alzheimer’s disease |
| topic | keratin 9 Alzheimer's disease |
| url | https://eprints.nottingham.ac.uk/32385/ https://eprints.nottingham.ac.uk/32385/ https://eprints.nottingham.ac.uk/32385/ |